A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials-Reference-Cited by-同舟云学术

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials

Published:2020-05 Issue: Volume:131 Page:89-97
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Berger Martin D.,Ning Yan,Stintzing Sebastian,Heinemann Volker,Cao Shu,Zhang Wu,Yang Dongyun,Miyamoto Yuji,Suenaga Mitsukuni,Schirripa Marta^ORCID,Hanna Diana L.,Soni Shivani^ORCID,Puccini Alberto,Tokunaga Ryuma,Naseem Madiha,Battaglin Francesca^ORCID,Cremolini Chiara,Falcone Alfredo,Loupakis Fotios,Lenz Heinz-Josef

Funder

Werner and Hedy Berger-Janser Foundation

National Cancer Institute, United States

Dhont Family Foundation, United States

Japan Society for the Promotion of Science, Japan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Stromal PD-1/PD-L1 expression predicts outcome in colon cancer patients;Wyss;Clin Colorectal Cancer,2019

2. A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab;Berger;Clin Cancer Res,2018